Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul J Bédard

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Neurobiology of Disease|June 23, 2004
The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeysPershia Samadi, Laurent Grégoire, Paul J Bédard
Trends in Pharmacological Sciences|August 16, 2006
Opioids and motor complications in Parkinson's diseasePershia Samadi, Paul J Bédard, Claude Rouillard
Neuropharmacology|October 24, 2003
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systemsPershia Samadi, Laurent Grégoire, Paul J Bédard
Neurobiology of Disease|April 20, 2005
Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeysPershia Samadi, Laurent Grégoire, Claude Rouillard, et al.
Neurobiology of Aging|October 29, 2005
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeysNancy Bélanger, Laurent Grégoire, Paul J Bédard, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 16, 2003
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeysNancy Bélanger, Laurent Grégoire, Abdallah Hadj Tahar, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 28, 2005
Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's diseaseRobert B McCall, Keith J Lookingland, Paul J Bédard, et al.
Neurobiology of Disease|December 18, 2003
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's diseaseFrédéric Calon, Ali H Rajput, Oleh Hornykiewicz, et al.
Neurobiology of Disease|March 10, 2004
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeysAbdallah Hadj Tahar, Laurent Grégoire, Aurélie Darré, et al.
Annals of Neurology|January 27, 2006
Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeysPershia Samadi, Laurent Grégoire, Claude Rouillard, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Neurobiology of Disease|June 23, 2004
The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeysPershia Samadi, Laurent Grégoire, Paul J Bédard
Trends in Pharmacological Sciences|August 16, 2006
Opioids and motor complications in Parkinson's diseasePershia Samadi, Paul J Bédard, Claude Rouillard
Neuropharmacology|October 24, 2003
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systemsPershia Samadi, Laurent Grégoire, Paul J Bédard
Neurobiology of Disease|April 20, 2005
Dyskinesias occur in response to saline and naltrexone alone after priming with combination of dopaminergic agents and naltrexone in the MPTP parkinsonian monkeysPershia Samadi, Laurent Grégoire, Claude Rouillard, et al.
Neurobiology of Aging|October 29, 2005
DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeysNancy Bélanger, Laurent Grégoire, Paul J Bédard, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|December 16, 2003
Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeysNancy Bélanger, Laurent Grégoire, Abdallah Hadj Tahar, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 28, 2005
Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's diseaseRobert B McCall, Keith J Lookingland, Paul J Bédard, et al.
Neurobiology of Disease|December 18, 2003
Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's diseaseFrédéric Calon, Ali H Rajput, Oleh Hornykiewicz, et al.
Neurobiology of Disease|March 10, 2004
Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeysAbdallah Hadj Tahar, Laurent Grégoire, Aurélie Darré, et al.
Annals of Neurology|January 27, 2006
Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeysPershia Samadi, Laurent Grégoire, Claude Rouillard, et al.
Pageof 3